Q3 Loss Widens to $85.8M as Cash Runway Extends Into 2028
IMNM sits 32% above its 52-week low of $14.64.
Summary
Immunome posted a Q3 net loss of $85.8 million, or $0.76 per share, versus $57.5 million a year ago, as R&D jumped to $69.5 million from $49.2 million and G&A rose to $20.9 million from $10.9 million. The company ended September with $461.6 million in cash, cash equivalents and marketable securities and says that funds operations into 2028. The pipeline update is the real story: varegacestat has an FDA PDUFA date of April 28, 2027, and the EMA validated the MAA in October 2026, while IM-1021 Phase 1 data are due at ASH on December 14, 2026. Three programs are now in the clinic, with IM-1340 expected to start Phase 1 by year-end. The burn is heavy but funded, so the near-term swing factor is the varegacestat approval decision and the ASH dataset.
At the time of this announcement, IMNM was trading at $19.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $14.64 to $30.06. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.